X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5443) 5443
Newsletter (235) 235
Book Chapter (12) 12
Dissertation (8) 8
Magazine Article (7) 7
Book / eBook (4) 4
Publication (4) 4
Newspaper Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3851) 3851
pharmacology & pharmacy (2189) 2189
male (2048) 2048
cytochrome p-450 (1927) 1927
animals (1903) 1903
female (1612) 1612
cytochrome p-450 enzyme system - metabolism (1513) 1513
metabolism (1378) 1378
cytochrome p-450 enzyme system - genetics (1376) 1376
cytochrome p450 (1196) 1196
toxicology (1049) 1049
adult (984) 984
enzymes (973) 973
cytochrome p-450 cyp1a2 - genetics (956) 956
middle aged (903) 903
genotype (832) 832
pharmacokinetics (824) 824
physiological aspects (780) 780
research (742) 742
cytochrome p-450 cyp1a2 - metabolism (740) 740
rats (732) 732
liver (725) 725
genetic aspects (663) 663
mice (646) 646
drug interactions (642) 642
pharmacogenetics (614) 614
expression (610) 610
analysis (603) 603
aged (594) 594
biochemistry & molecular biology (589) 589
cytochrome p-450 cyp1a1 - genetics (580) 580
liver - enzymology (573) 573
polymorphism, genetic (565) 565
induction (553) 553
in-vitro (545) 545
cytochrome (514) 514
cyp1a2 (496) 496
gene expression (496) 496
metabolites (492) 492
liver - drug effects (490) 490
cancer (488) 488
microsomes, liver - enzymology (460) 460
aryl hydrocarbon hydroxylases - genetics (455) 455
polymorphism (449) 449
liver - metabolism (443) 443
cytochrome p-450 cyp1a1 - metabolism (442) 442
oncology (431) 431
genetic polymorphisms (423) 423
pharmacology/toxicology (403) 403
drug metabolism (400) 400
genes (397) 397
rna, messenger - metabolism (389) 389
biotransformation (387) 387
phenotype (386) 386
dose-response relationship, drug (361) 361
pharmacology (361) 361
inhibition (360) 360
risk factors (357) 357
microsomes, liver - metabolism (355) 355
aryl hydrocarbon hydroxylases - metabolism (346) 346
human liver-microsomes (324) 324
health aspects (320) 320
toxicity (315) 315
caffeine (314) 314
kinetics (306) 306
polymorphism, single nucleotide (306) 306
drugs (300) 300
cytochrome p-450 cyp2d6 - genetics (299) 299
genetics & heredity (298) 298
rna, messenger - genetics (298) 298
gene-expression (297) 297
biomedicine (296) 296
cells, cultured (294) 294
cytochrome p-450 enzyme system - biosynthesis (294) 294
microsomes, liver - drug effects (293) 293
cytochrome p-450 cyp3a - metabolism (292) 292
proteins (291) 291
hydroxylation (286) 286
young adult (285) 285
genetic research (284) 284
cytochrome p-450 cyp3a (279) 279
cytochrome p-450 enzyme inhibitors (277) 277
alleles (270) 270
isoenzymes - metabolism (263) 263
rats, sprague-dawley (263) 263
activation (262) 262
cyp2d6 (258) 258
drug-metabolism (258) 258
enzyme inhibitors - pharmacology (255) 255
polymorphisms (251) 251
cytochromes p450 (248) 248
aryl-hydrocarbon receptor (238) 238
cyp1a1 (237) 237
rodents (236) 236
medicine (235) 235
medicine & public health (235) 235
cytochrome p-450 cyp2d6 - metabolism (234) 234
risk (234) 234
adolescent (233) 233
smoking (233) 233
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5688) 5688
Japanese (55) 55
Chinese (23) 23
Russian (13) 13
German (11) 11
Polish (6) 6
French (5) 5
Portuguese (3) 3
Croatian (1) 1
Czech (1) 1
Dutch (1) 1
Italian (1) 1
Norwegian (1) 1
Slovak (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Drug metabolism and disposition, ISSN 1521-009X, 2010, Volume 38, Issue 1, pp. 92 - 99
.... CYP1A2, CYP2B6, and CYP2C19 catalyzed this reaction. In the same system using 2-oxo-clopidogrel as the substrate, detection of the active metabolite of clopidogrel required the addition of glutathione to the system... 
MECHANISM-BASED INHIBITION | ANTIAGGREGATING ACTIVITY | POLYMORPHISMS | PHARMACOKINETICS | TICLOPIDINE | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS | MONOCLONAL-ANTIBODIES | Microsomes - metabolism | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Cytochrome P-450 Enzyme System - metabolism | Sulfaphenazole - pharmacology | Microsomes - drug effects | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Antibodies - immunology | Omeprazole - pharmacology | Microsomes, Liver - enzymology | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - immunology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Ticlopidine - analogs & derivatives | Oxidoreductases, N-Demethylating - immunology | Cytochrome P-450 CYP3A - metabolism | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Theophylline - pharmacology | Kinetics | Cytochrome P-450 CYP2C9 | Theophylline - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Glutathione - metabolism | Ketoconazole - pharmacology | Biotransformation - physiology | Cytochrome P-450 CYP1A2 Inhibitors | Microsomes, Liver - drug effects | Ticlopidine - metabolism | NADP - metabolism | Platelet Aggregation Inhibitors - metabolism | Cytochrome P-450 CYP3A - immunology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 - immunology | Biocatalysis | Mephenytoin - analogs & derivatives | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Mephenytoin - pharmacology | Antibodies - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP2C19 | Clopidogrel | Cytochrome P-450 CYP2B6
Journal Article
PloS one, ISSN 1932-6203, 04/2014, Volume 9, Issue 4, p. e93261
...). Using real time quantitative RT-PCR, the gene expression pattern of CYP1A1, CYP1A2, CYP1B1, CYP2E1, CYP2W1, CYP3A4, and CYP3A5 were analyzed in tumor and adjacent non-tumor tissues from 13 child RMS patients... 
CYP3A4/5 | CYP2W1 | METABOLISM | CANCER | MULTIDISCIPLINARY SCIENCES | CHILDREN | Cytochrome P-450 CYP1A1 - genetics | Cytochrome P-450 CYP1B1 - genetics | Prospective Studies | Follow-Up Studies | Humans | Rhabdomyosarcoma - metabolism | Gene Expression Regulation, Neoplastic | Child, Preschool | Cytochrome P-450 Enzyme System - metabolism | Cytochrome P-450 CYP1B1 - metabolism | Infant | Male | Muscle, Skeletal - metabolism | Cytochrome P-450 CYP2E1 - genetics | Gene Expression Profiling | Cytochrome P-450 CYP2E1 - metabolism | Cytochrome P450 Family 2 | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Biomarkers, Tumor - metabolism | Female | Child | Real-Time Polymerase Chain Reaction | RNA, Messenger - genetics | Cytochrome P-450 CYP1A1 - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Cytochrome P-450 CYP1A2 - metabolism | Blotting, Western | Gene Expression Regulation, Enzymologic | Cytochrome P-450 CYP3A - metabolism | Adolescent | Cytochrome P-450 Enzyme System - genetics | Biomarkers, Tumor - genetics | Rhabdomyosarcoma - genetics | Cytochrome | Drugs | Rhabdomyosarcoma | Chemoresistance | Families & family life | Drug development | Tissues | Cancer therapies | Antitumor agents | Rodents | Drug metabolism | Children | Enzymes | Prodrugs | Cytochrome P450 | CYP gene | CYP1A2 protein | Metabolism | Gene expression | Chemical compounds | Patients | Polymerase chain reaction | Musculoskeletal system | Chemotherapy | Tumors | Cancer
Journal Article
Drug metabolism and disposition, ISSN 1521-009X, 2008, Volume 36, Issue 12, pp. 2547 - 2555
.... CYP1A2 is generally considered to be the major enzyme involved in the biotransformation of CLZ to its N -demethylated (norCLZ) and N -oxygenated (CLZ N -oxide... 
SEROTONIN REUPTAKE INHIBITORS | IN-VITRO | SERUM CONCENTRATIONS | METABOLISM | N-DESMETHYLCLOZAPINE | ALLELIC VARIANTS | FLUVOXAMINE | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | FUNCTIONAL-CHARACTERIZATION | CYP3A4 | Cytochrome P-450 CYP2C9 | Clozapine - metabolism | Oxidoreductases, N-Demethylating - genetics | Cytochrome P-450 Enzyme Inhibitors | Humans | Microsomes, Liver - metabolism | Aryl Hydrocarbon Hydroxylases - genetics | Biotransformation - genetics | Cytochrome P-450 Enzyme System - metabolism | Dextromethorphan - metabolism | Ketoconazole - pharmacology | Oxygenases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 Inhibitors | Testosterone - metabolism | Cytochrome P-450 CYP3A - genetics | Isoenzymes - metabolism | Microsomes, Liver - drug effects | Oxygenases - metabolism | Cytochrome P-450 CYP1A2 - genetics | Catalysis | Oxidoreductases, N-Demethylating - metabolism | Tolbutamide - metabolism | Recombinant Proteins - metabolism | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Oxidation-Reduction | Isoenzymes - genetics | Enzyme Inhibitors - pharmacology | Clozapine - analogs & derivatives | Cytochrome P-450 CYP1A1 - metabolism | Cytochrome P-450 CYP1A2 - metabolism | Fluvoxamine - pharmacology | Aryl Hydrocarbon Hydroxylases - metabolism | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP3A - metabolism | Biotransformation - drug effects | Alleles | Cytochrome P-450 Enzyme System - genetics | Kinetics | Oxygenases - genetics | Cytochrome P-450 CYP2B6 | Isoenzymes - antagonists & inhibitors
Journal Article
Cancer Epidemiology Biomarkers & Prevention, ISSN 1055-9965, 07/2007, Volume 16, Issue 7, pp. 1460 - 1467
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2013, Volume 110, Issue 27, pp. 11115 - 11120
Smoking is a major risk factor for osteoporosis and fracture, but the mechanism through which smoke causes bone loss remains unclear. Here, we show that the... 
Bone resorption | Enzymes | Cell lines | Stem cells | Bones | Osteoclasts | Cultured cells | Bone marrow cells | Cigarette smoking | Aryl hydrocarbon receptors | Osteoblast | Skeletal remodeling | Toxicology | Bone formation | toxicology | TARGET | RESORPTION | MULTIDISCIPLINARY SCIENCES | osteoblast | AHR | skeletal remodeling | CANCER | IN-VITRO | INHIBITION | METABOLISM | bone formation | CIGARETTE-SMOKE | HEALTH | OSTEOCLAST DIFFERENTIATION | Smoking - adverse effects | Cytochrome P-450 CYP1A1 - genetics | Receptors, Aryl Hydrocarbon - deficiency | Aryl Hydrocarbon Hydroxylases - biosynthesis | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Carcinogens - toxicity | Cytochrome P-450 CYP1A2 - genetics | Cytochrome P-450 CYP1A2 - deficiency | Bone Resorption - metabolism | Female | Cytochrome P-450 CYP1A1 - deficiency | Disease Models, Animal | Bone Resorption - etiology | Benzo(a)pyrene - toxicity | Smoke - adverse effects | Mice, Inbred C57BL | Receptors, Aryl Hydrocarbon - genetics | Smoking - genetics | Receptors, Aryl Hydrocarbon - physiology | Tobacco - toxicity | Mice, Knockout | Enzyme Induction - genetics | Animals | Aryl Hydrocarbon Hydroxylases - deficiency | Cytochrome P-450 CYP1A2 - biosynthesis | Bone Resorption - pathology | Cytochrome P-450 CYP1B1 | Polychlorinated Dibenzodioxins - toxicity | Mice | Cytochrome P-450 CYP1A1 - biosynthesis | Osteoporosis | Carcinogens | Cocarcinogens | Hydrocarbons | Physiological aspects | Health aspects | Smoking | Index Medicus | Biological Sciences
Journal Article
Toxicological sciences, ISSN 1096-0929, 2012, Volume 125, Issue 2, pp. 345 - 358
.... Herein, we evaluated AAI metabolism by human cytochrome P450 (CYP) 1A1 and 1A2 in two CYP1A-humanized mouse lines that carry functional human CYP1A1 and CYP1A2 genes in the absence of the mouse Cyp1a1/1a2 orthologs... 
Aristolochic acid ia | Cytochrome P450 | Cyp1a-humanized mouse models | Balkan endemic nephropathy | Metabolism | Aristolochic acid nephropathy | Dna adducts | aristolochic acid nephropathy | DNA-ADDUCTS | P450 1A1 | PHASE-II | METABOLIC-ACTIVATION | cytochrome P450 | MOUSE LINE | RISK-FACTOR | REDUCTIVE ACTIVATION | GENE-EXPRESSION | metabolism | TOXICOLOGY | DNA adducts | CYP1A-humanized mouse models | aristolochic acid Ia | CHINESE HERBS | Cytochrome P-450 CYP1A1 - genetics | Inactivation, Metabolic | Liver - enzymology | Humans | Cytochrome P-450 CYP1A1 - antagonists & inhibitors | Chromatography, High Pressure Liquid | Carcinogens - metabolism | Aristolochic Acids - urine | DNA Adducts - metabolism | Carcinogens - toxicity | Cytochrome P-450 CYP1A2 Inhibitors | Cytosol - enzymology | Liver - drug effects | Cytochrome P-450 CYP1A2 - genetics | Female | Microsomes, Liver - enzymology | Aristolochic Acids - toxicity | Recombinant Proteins - metabolism | Oxidation-Reduction | Dealkylation | Mice, Inbred C57BL | Enzyme Inhibitors - pharmacology | Mice, Transgenic | Urologic Neoplasms - chemically induced | Cytochrome P-450 CYP1A1 - metabolism | Cytochrome P-450 CYP1A2 - metabolism | Mice, Knockout | Animals | Aristolochic Acids - metabolism | Mice | Urothelium - drug effects | Index Medicus | Biotransformation and Toxicokinetics
Journal Article
PloS one, ISSN 1932-6203, 09/2015, Volume 10, Issue 9, pp. e0138875 - e0138875
To investigate the auto-induction of cytochrome P450 (CYP450) by Chloroxoquinoline (CXL), a novel anticancer drug. Three experiments related to the induction... 
VITRO | COCKTAIL | METABOLISM | DRUG-INTERACTIONS | HUMAN HEPATOCYTES | MULTIDISCIPLINARY SCIENCES | IN-VIVO | INDUCTION | Cytochrome P-450 CYP1A2 Inducers - pharmacology | Cells, Cultured | Male | Cytochrome P-450 CYP1A2 - metabolism | Rats, Sprague-Dawley | Quinolines - pharmacology | Cytochrome P-450 CYP1A2 Inducers - pharmacokinetics | Quinolines - pharmacokinetics | Animals | Cytochrome P-450 CYP3A Inducers - pharmacology | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP3A - metabolism | Cytochrome P-450 CYP1A2 - genetics | Cytochrome P-450 CYP3A Inducers - pharmacokinetics | Enzyme Induction - drug effects | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Kinetics | Hepatocytes - drug effects | Hepatocytes - enzymology | Complications and side effects | Chemotherapy | Cytochrome P-450 | Physiological aspects | Quinoline | Genetic aspects | Dosage and administration | Research | Cancer | Cytochrome | CYP1A protein | Life assessment | mRNA | Cancer therapies | Toxicology | Metabolites | Rodents | Pretreatment | Inducers | Caffeine | Enzymes | Cytochrome P450 | Rats | Pharmacology | Liquid chromatography | FDA approval | Metabolism | Gene expression | High-performance liquid chromatography | Polymerase chain reaction | Studies | Pathology | Hepatocytes | Pharmacy | In vivo methods and tests | Pharmaceuticals | Index Medicus
Journal Article